A large clinical trial in South Africa and Uganda has shown that a twice-yearly injection of a new pre-exposure prophylaxis drug gives young women total protection from HIV infection.
The trial tested whether the six-month injection of lenacapavir would provide better protection against HIV infection than two other pre-exposure drugs, both daily pills.
For more on what makes this breakthrough so significant and what to expect next, we're joined virtually by the deputy director of the Desmond Tutu HIV Centre at the Institute of Infectious Disease and Molecular Medicine at the University of Cape town, Prof Linda-Gail Bekker.
For more news, visit sabcnews.com and #SABCNews on all Social Media platforms.
